Conventional and Genetic Association Between Migraine and Stroke with Druggable Genome-wide Mendelian Randomization

Overview

Journal Hum Genet

Date 2025 Jan 22

PMID 39841246

Authors

Xiaoyu Wang

Wendu Pang

Xin Hu

Tao Shu

Yaxin Luo

Junhong Li

Lan Feng

Ke Qiu

Yufang Rao

Yao Song

Minzi Mao

Yuyang Zhang

Jianjun Ren

Yu Zhao

Affiliations

Soon will be listed here.

Abstract

The genetic relationship between migraine and stroke remains underexplored, particularly in the context of druggable targets. Previous studies have been limited by small sample sizes and a lack of focus on genetic-targeted therapies for these conditions. We analyzed the association and causality between migraine and stroke using multivariable logistic regression in the UK Biobank cohort and Mendelian randomization (MR) analyses based on genome-wide association study (GWAS) data. Integrating expression quantitative trait loci (eQTLs) data from blood and brain regions, we explored the phenotypic and genetic links between migraine medications, drug target, and stroke. Additionally, we explored novel druggable genes for migraine and evaluated their effects on migraine signaling molecules and stroke risk. Migraine was significantly associated with stroke, particularly ischemic stroke (IS) and intracerebral hemorrhage (ICH), with MR analysis confirming a causal link to ICH. HTR1A emerged as a potential link between antidepressants (preventive medications for migraine) and stroke. We identified 17 migraine-related druggable genes, with 5 genes (HMGCR, TGFB1, TGFB3, KCNK5, IMPDH2) associated with nine existing drugs. Further MR analysis identified correlation of CELSR3 and IMPDH2 with cGMP pathway marker PRKG1, and identified KCNK5, PLXNB1, and MDK as novel migraine-associated druggable genes significantly linked to the stroke risks. These findings established the phenotypic and genetic link between migraine, its medication and stroke, identifying potential targets for single and dual-purpose therapies for migraine and stoke, and emphasized the need for further research to validate these associations.

References

Adelborg K, Szepligeti S, Holland-Bill L, Ehrenstein V, Horvath-Puho E, Henderson V . Migraine and risk of cardiovascular diseases: Danish population based matched cohort study. BMJ. 2018; 360:k96. PMC: 5791041. DOI: 10.1136/bmj.k96. View

Baigent C, Keech A, Kearney P, Blackwell L, Buck G, Pollicino C . Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366(9493):1267-78. DOI: 10.1016/S0140-6736(05)67394-1. View

Battle A, Brown C, Engelhardt B, Montgomery S . Genetic effects on gene expression across human tissues. Nature. 2017; 550(7675):204-213. PMC: 5776756. DOI: 10.1038/nature24277. View

Berkovich R, Sokolov A, Togasaki D, Yakupova A, Cesar P, Sahai-Srivastava S . Dextromethorphan/Quinidine in Migraine Prophylaxis: An Open-label Observational Clinical Study. Clin Neuropharmacol. 2018; 41(2):64-69. DOI: 10.1097/WNF.0000000000000272. View

Bi Y, Zhu Y, Tang S, Huang Y . Lipids, lipid-modifying drug target genes and migraine: a Mendelian randomization study. J Headache Pain. 2023; 24(1):112. PMC: 10439594. DOI: 10.1186/s10194-023-01633-x. View

Buettner C, Nir R, Bertisch S, Bernstein C, Schain A, Mittleman M . Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial. Ann Neurol. 2015; 78(6):970-81. PMC: 4715556. DOI: 10.1002/ana.24534. View

Crisan E, Patil V . Neuromuscular Complications of Statin Therapy. Curr Neurol Neurosci Rep. 2020; 20(10):47. DOI: 10.1007/s11910-020-01064-0. View

Davies N, Holmes M, Davey Smith G . Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018; 362:k601. PMC: 6041728. DOI: 10.1136/bmj.k601. View

de Klein N, Tsai E, Vochteloo M, Baird D, Huang Y, Chen C . Brain expression quantitative trait locus and network analyses reveal downstream effects and putative drivers for brain-related diseases. Nat Genet. 2023; 55(3):377-388. PMC: 10011140. DOI: 10.1038/s41588-023-01300-6. View

10.

Dreier J, Fabricius M, Ayata C, Sakowitz O, Shuttleworth C, Dohmen C . Recording, analysis, and interpretation of spreading depolarizations in neurointensive care: Review and recommendations of the COSBID research group. J Cereb Blood Flow Metab. 2016; 37(5):1595-1625. PMC: 5435289. DOI: 10.1177/0271678X16654496. View

11.

Eigenbrodt A, Ashina H, Khan S, Diener H, Mitsikostas D, Sinclair A . Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021; 17(8):501-514. PMC: 8321897. DOI: 10.1038/s41582-021-00509-5. View

12.

Ferrari M, Goadsby P, Burstein R, Kurth T, Ayata C, Charles A . Migraine. Nat Rev Dis Primers. 2022; 8(1):2. DOI: 10.1038/s41572-021-00328-4. View

13.

Finan C, Gaulton A, Kruger F, Lumbers R, Shah T, Engmann J . The druggable genome and support for target identification and validation in drug development. Sci Transl Med. 2017; 9(383). PMC: 6321762. DOI: 10.1126/scitranslmed.aag1166. View

14.

Freshour S, Kiwala S, Cotto K, Coffman A, McMichael J, Song J . Integration of the Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts. Nucleic Acids Res. 2020; 49(D1):D1144-D1151. PMC: 7778926. DOI: 10.1093/nar/gkaa1084. View

15.

Giambartolomei C, Vukcevic D, Schadt E, Franke L, Hingorani A, Wallace C . Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014; 10(5):e1004383. PMC: 4022491. DOI: 10.1371/journal.pgen.1004383. View

16.

Guo Y, Daghlas I, Gormley P, Giulianini F, Ridker P, Mora S . Phenotypic and Genotypic Associations Between Migraine and Lipoprotein Subfractions. Neurology. 2021; 97(22):e2223-e2235. PMC: 8641972. DOI: 10.1212/WNL.0000000000012919. View

17.

Ha H, Gonzalez A . Migraine Headache Prophylaxis. Am Fam Physician. 2019; 99(1):17-24. View

18.

Hautakangas H, Winsvold B, Ruotsalainen S, Bjornsdottir G, Harder A, Kogelman L . Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles. Nat Genet. 2022; 54(2):152-160. PMC: 8837554. DOI: 10.1038/s41588-021-00990-0. View

19.

Kadomatsu K, Bencsik P, Gorbe A, Csonka C, Sakamoto K, Kishida S . Therapeutic potential of midkine in cardiovascular disease. Br J Pharmacol. 2013; 171(4):936-44. PMC: 3925033. DOI: 10.1111/bph.12537. View

20.

Kuo C, Yen M, Chen L, Fann C, Chiu Y, Chen H . Increased risk of hemorrhagic stroke in patients with migraine: a population-based cohort study. PLoS One. 2013; 8(1):e55253. PMC: 3555928. DOI: 10.1371/journal.pone.0055253. View